Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, PR China.
Department of Genetics, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, P. O. Box 1982, Dammam, 31441, Saudi Arabia.
Eur J Pharmacol. 2020 Nov 5;886:173447. doi: 10.1016/j.ejphar.2020.173447. Epub 2020 Aug 5.
Coronavirus Disease 2019 (COVID-19) caused by a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was first reported in Wuhan, China at the end of December 2019. SARS-CoV-2 is a highly pathogenic zoonotic virus and closely related to the Severe Acute Respiratory Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The COVID-19 was declared as a global pandemic due to its high infectiousness, and worldwide morbidities and mortalities. The Chinese scientists at the start of the outbreak reported genome sequences, which made the characterization of glycoproteins and other structural proteins possible. Moreover, researchers across the world have widely focused on understanding basic biology, developing vaccines, and therapeutic drugs against the COVID-19. However, until now, no promising treatment options, as well as vaccines, are available. In this review, we have described SARS-CoV-2's genome, transmission, and pathogenicity. We also discussed novel potential therapeutic agents that can help to treat the COVID-19 patients.
2019 年冠状病毒病（COVID-19）由一种严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）引起，最初于 2019 年 12 月底在中国武汉报告。SARS-CoV-2 是一种高致病性人畜共患病病毒，与严重急性呼吸系统综合征冠状病毒（SARS-CoV）和中东呼吸系统综合征冠状病毒（MERS-CoV）密切相关。由于其高度传染性以及全球发病率和死亡率，COVID-19 被宣布为全球大流行。疫情爆发初期，中国科学家报告了基因组序列，这使得糖蛋白和其他结构蛋白的特征得以确定。此外，世界各地的研究人员广泛关注对 COVID-19 的基础生物学、疫苗开发和治疗药物的研究。然而，到目前为止，尚无有效的治疗选择和疫苗可用。在这篇综述中，我们描述了 SARS-CoV-2 的基因组、传播和致病性。我们还讨论了一些新型有潜力的治疗药物，这些药物可能有助于治疗 COVID-19 患者。
